Stem cell research.
Sometimes a post here on The Niche (named after the stem cell niche) sparks a debate between expert stem cell researchers and often that gives much more depth to a topic. Such was the case with my post this week on where things stand with stem cell therapy for heart disease. It led to a […]
Weekly reads: Melton leaves Harvard, Fuji, BBC blunder, stem cell niche, more Read More »
How much promise is there today for stem cell therapy for heart disease? Where do things stand with the clinical research? Patients regularly ask me these kinds of questions. The goal of today’s post is to update you on where things stand. What’s in this post Stem Cell Therapy | Clinical Trials | Delivery of
Stem cell therapy for heart disease: what you need to know Read More »
David Weinberg over at Science-Based Medicine has his part two of a deep dive into the so-called SCOTS trial, which is a non-traditional pay-for-play study. I highly recommend it. SCOTS trial under the magnifying glass In this piece, Weinberg provides interesting background on the two people running SCOTS. I’ve had many concerns about the SCOTS
Recommended reads: engineered niche, ALS, SCOTS trial, human genome “done” Read More »
Science must go on and so must stem cell meetings in 2022 with all those great conferences out there, but hopefully this year will be better than 2020-2021. It seems that way with the pandemic easing in the U.S. and many other places. On the other hand, COVID is spiking in Asia and other regions.
Hub of Regenerative Medicine & Stem Cell Meetings 2022 Read More »
When it comes to stem cells on Twitter and other social media, who do you follow now? Why them? Who are the top stem cell and regenerative medicine influencers to follow on Twitter and elsewhere in 2022? Stem cells on Twitter: great content amongst the noise Top stem cell and regenerative medicine influencers on Twitter.
50 influencers on stem cells on Twitter to follow in 2022 Read More »
It’s been quite a ride doing this blog on stem cells and other technologies for more than a dozen years. So far it seems like I’ll keep it going. A large part of the reason is because of people needing good information about our field. Those people include scientists and physicians but also many in
Weekly reads: Google, stem cells & MS, VSELs, ‘hairy’ organoids, MYC Read More »
Many firms that generally fall into the category of unproven stem cell or cell therapy clinics have a way of reinventing themselves and I’ve seen this with one formerly named the Lung Institute that is now called Centers for Respiratory Health. First the Lung Institute became the Lung Health Institute. Now that firm has become
Centers for Respiratory Health is new incarnation of clinic Lung Health Institute Read More »
The FDA has been busy with the COVID pandemic but it has many other things on its plate as well including cell therapies. Today I’m sharing some recent agency news and brief perspectives on it. FDA focus on clinic-related umbilical cord cell drug makers The agency warned an Idaho company that produces and sells umbilical
FDA news: warning letter pattern, cancer moonshot, CAR-T & gene-editing guidance Read More »
The big news of the week was a $3.6 million settlement by a stem cell clinic, StemGenex, and one of its doctors in a class-action suit. I covered this StemGenex settlement and so did Michael Hiltzik of the LA Times and Paul Schloesser at Endpoints. I’d say this was good news for the stem cell field
Stem cell weekly reads: Jamie Thomson, Lamin B1, CRISPR Read More »
I’m fascinated by the idea of making food from cells grown in a lab and especially the newest idea of lab-grown chocolate. While lab-grown meat has gotten the most attention, (see my recent post on test-tube meat: Not Old MacDonald’s Farm: is the future lab-grown meat?) I’d say that the coolest application of making food from
Biotech California Cultured aims to sell lab-grown chocolate Read More »